Lead Product(s) : Calcium Ion
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : CSL Behring
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Factor XIII is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Scleroderma, Systemic.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
September 16, 2015
Lead Product(s) : Calcium Ion
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : CSL Behring
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
